Ulipristal acetate emergency contraception access and dispensing in Alberta, Canada, from 2015–2023

Key Points

• Access to ulipristal acetate for emergency contraception has steadily increased since its approval in Alberta.
• First-year uptake lagged compared to other medications, suggesting underlying barriers to adoption.
• Equitable access to emergency contraception involves addressing clinician awareness and patient education need.
• Policy support will play a crucial role in maintaining and improving access to ulipristal acetate.

Abstract